Navigating The Evolving Landscape of Adalimumab Biosimilars for Inflammatory Disease
EP. 1: The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.
EP. 2: An Overview of Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.
EP. 3: The Pharmacological Aspects of Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.
EP. 4: The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter A. Lio, MD, Northwestern University Feinberg School of Medicine Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.
EP. 5: Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.
EP. 6: The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.
EP. 7: Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.
EP. 8: Selecting Between Adalimumab Biosimilars for Your Patients
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.
EP. 9: Switching From Adalimumab to a Biosimilar
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.
EP. 10: Clinical Experience With Initiating Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.
EP. 11: The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.
EP. 12: Copay Assistance Programs for Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.
EP. 13: Common Questions From Patients About Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.
EP. 14: The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.
EP. 15: Resources for Patients and Providers on Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
